



## Public Testimony Registration

1 message

**PSWebteam@magellanhealth.com** <PSWebteam@magellanhealth.com>  
To: AHCCCSPharmacyDept@azahcccs.gov, douikih@magellanhealth.com  
Cc: chiranjir\_narine@dmgaz.org

Mon, Dec 20, 2021 at 10:07 AM

Requestor Name: Chiranjir Narine MD  
Requestor Company: District Medical Group  
Requestor Address1: [5102 W Campbell Ave](#)  
Requestor Address2:  
Requestor City: Phoenix  
Requestor State: AZ  
Requestor ZipCode: 85031-  
Requestor Preferred Email Address: [chiranjir\\_narine@dmgaz.org](mailto:chiranjir_narine@dmgaz.org)  
Requestor Telephone #: 602.655.1052  
Requestor Fax #: ..  
Representing Other?  
Representative of:  
Non-affiliated/private?  
Statement of No Conflicts:Yes  
Disclosures:  
Organization1/Role1: /  
Organization2/Role2: /  
Organization3/Role3: /  
Organization4/Role4: /  
Summary of Testimony: I would like to encourage a continued open access to psychotropic agents that have demonstrated clinical value. These include long-acting atypical antipsychotics (LAIs), oral atypical second-generation antipsychotics, stimulants and related agents, and opiate dependence treatments such as MAT (medication assisted treatments).  
Drug/Product: long-acting atypical antipsychotics (LAIs), oral atypical second-generation antipsychotics, stimulants and related agents, and opiate dependence treatments such as MAT (medication assisted treatments). Request adding more Long acting atypical antipsychotics with 6 weeks and 3 month formulation such as Aripiprazole lauroxil (Aristada) and Invega Trinza.  
Therapeutic Drug Class: long-acting atypical antipsychotics (LAIs), oral atypical second-generation antipsychotics, stimulants and related agents, and opiate dependence treatments such as MAT (medication assisted treatments).  
Testimony Oral? Yes  
Testimony Written? Yes

\*\*\*Confidentiality Notice\*\*\* This electronic message transmission contains information belonging to Magellan Health, its subsidiaries or affiliates, that is solely for the recipient named above and which may be confidential or privileged. MAGELLAN HEALTH, its subsidiaries or affiliates, EXPRESSLY PRESERVES AND ASSERTS ALL PRIVILEGES AND IMMUNITIES APPLICABLE TO THIS TRANSMISSION. If you are not the intended recipient, be aware that any disclosure, copying, distribution or use of this communication is STRICTLY PROHIBITED. If you have received this electronic transmission in error, please notify us at . Thank you.